Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia
Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduc...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 1986-04, Vol.57 (11), p.933-939 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 939 |
|---|---|
| container_issue | 11 |
| container_start_page | 933 |
| container_title | The American journal of cardiology |
| container_volume | 57 |
| creator | Hoeg, Jeffrey M. Maher, Martha B. Zech, Loren A. Bailey, Kent R. Gregg, Richard E. Lackner, Karl J. Fojo, Silvia S. Anchors, Michael A. Bojanovski, Marina Sprecher, Dennis L. Brewer, H.Bryan |
| description | Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p < 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p < 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations. |
| doi_str_mv | 10.1016/0002-9149(86)90733-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76775494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002914986907332</els_id><sourcerecordid>76775494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-796ccceea4656bf16f3008b92283e863e1675ee1de0f7982c584a75f707a04d33</originalsourceid><addsrcrecordid>eNp9kU1rGzEQhkVpcJyk_6CFPYSQHDaRVquvS6EYJzEEcmnPQtaOqMqutJHWBv_7yLExOfU0aOaZV-IRQt8JvieY8AeMcVMr0qpbye8UFpTWzRc0J1KomihCv6L5CTlHFzn_K0dCGJ-hGWWESSXmSC-dAzv5LQTIuYquGmDrQ-x9qGKoxt7kwVS9H-OY4gSla2OwEKZkJh9Drkpn2o1QrVbV31LTJxQGb67QmTN9hm_Heon-PC5_L57rl9en1eLXS21b1ky1UNxaC2BazvjaEe4oxnKtmkZSkJwC4YIBkA6wE0o2lsnWCOYEFga3HaWX6OaQW-5-20Ce9OCzhb43AeIma8GFYK1qC9geQJtizgmcHpMfTNppgvXeq95L03tpWnL94VU3Ze3HMX-zHqA7LR1Flvn1cW6yNb1LJlifT5jkhaP7mJ8HDIqLrYeks_VQhHY-lW_QXfT_f8c74QKVPw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76775494</pqid></control><display><type>article</type><title>Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hoeg, Jeffrey M. ; Maher, Martha B. ; Zech, Loren A. ; Bailey, Kent R. ; Gregg, Richard E. ; Lackner, Karl J. ; Fojo, Silvia S. ; Anchors, Michael A. ; Bojanovski, Marina ; Sprecher, Dennis L. ; Brewer, H.Bryan</creator><creatorcontrib>Hoeg, Jeffrey M. ; Maher, Martha B. ; Zech, Loren A. ; Bailey, Kent R. ; Gregg, Richard E. ; Lackner, Karl J. ; Fojo, Silvia S. ; Anchors, Michael A. ; Bojanovski, Marina ; Sprecher, Dennis L. ; Brewer, H.Bryan</creatorcontrib><description>Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p < 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p < 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/0002-9149(86)90733-2</identifier><identifier>PMID: 3515897</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Anticholesteremic Agents - therapeutic use ; Apolipoproteins B - blood ; Biological and medical sciences ; Cholesterol - blood ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Cholesterol, VLDL ; Clinical Trials as Topic ; Double-Blind Method ; Female ; General and cellular metabolism. Vitamins ; Humans ; Hyperlipoproteinemia Type II - diet therapy ; Hyperlipoproteinemia Type II - drug therapy ; Lipids - blood ; Lipoproteins - blood ; Lipoproteins, VLDL - blood ; Lovastatin ; Male ; Medical sciences ; Middle Aged ; Naphthalenes - therapeutic use ; Pharmacology. Drug treatments ; Placebos ; Random Allocation ; Triglycerides - blood</subject><ispartof>The American journal of cardiology, 1986-04, Vol.57 (11), p.933-939</ispartof><rights>1986</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-796ccceea4656bf16f3008b92283e863e1675ee1de0f7982c584a75f707a04d33</citedby><cites>FETCH-LOGICAL-c452t-796ccceea4656bf16f3008b92283e863e1675ee1de0f7982c584a75f707a04d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0002914986907332$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8651532$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3515897$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoeg, Jeffrey M.</creatorcontrib><creatorcontrib>Maher, Martha B.</creatorcontrib><creatorcontrib>Zech, Loren A.</creatorcontrib><creatorcontrib>Bailey, Kent R.</creatorcontrib><creatorcontrib>Gregg, Richard E.</creatorcontrib><creatorcontrib>Lackner, Karl J.</creatorcontrib><creatorcontrib>Fojo, Silvia S.</creatorcontrib><creatorcontrib>Anchors, Michael A.</creatorcontrib><creatorcontrib>Bojanovski, Marina</creatorcontrib><creatorcontrib>Sprecher, Dennis L.</creatorcontrib><creatorcontrib>Brewer, H.Bryan</creatorcontrib><title>Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p < 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p < 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations.</description><subject>Adult</subject><subject>Aged</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Apolipoproteins B - blood</subject><subject>Biological and medical sciences</subject><subject>Cholesterol - blood</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Cholesterol, VLDL</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hyperlipoproteinemia Type II - diet therapy</subject><subject>Hyperlipoproteinemia Type II - drug therapy</subject><subject>Lipids - blood</subject><subject>Lipoproteins - blood</subject><subject>Lipoproteins, VLDL - blood</subject><subject>Lovastatin</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Naphthalenes - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>Random Allocation</subject><subject>Triglycerides - blood</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1rGzEQhkVpcJyk_6CFPYSQHDaRVquvS6EYJzEEcmnPQtaOqMqutJHWBv_7yLExOfU0aOaZV-IRQt8JvieY8AeMcVMr0qpbye8UFpTWzRc0J1KomihCv6L5CTlHFzn_K0dCGJ-hGWWESSXmSC-dAzv5LQTIuYquGmDrQ-x9qGKoxt7kwVS9H-OY4gSla2OwEKZkJh9Drkpn2o1QrVbV31LTJxQGb67QmTN9hm_Heon-PC5_L57rl9en1eLXS21b1ky1UNxaC2BazvjaEe4oxnKtmkZSkJwC4YIBkA6wE0o2lsnWCOYEFga3HaWX6OaQW-5-20Ce9OCzhb43AeIma8GFYK1qC9geQJtizgmcHpMfTNppgvXeq95L03tpWnL94VU3Ze3HMX-zHqA7LR1Flvn1cW6yNb1LJlifT5jkhaP7mJ8HDIqLrYeks_VQhHY-lW_QXfT_f8c74QKVPw</recordid><startdate>19860415</startdate><enddate>19860415</enddate><creator>Hoeg, Jeffrey M.</creator><creator>Maher, Martha B.</creator><creator>Zech, Loren A.</creator><creator>Bailey, Kent R.</creator><creator>Gregg, Richard E.</creator><creator>Lackner, Karl J.</creator><creator>Fojo, Silvia S.</creator><creator>Anchors, Michael A.</creator><creator>Bojanovski, Marina</creator><creator>Sprecher, Dennis L.</creator><creator>Brewer, H.Bryan</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19860415</creationdate><title>Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia</title><author>Hoeg, Jeffrey M. ; Maher, Martha B. ; Zech, Loren A. ; Bailey, Kent R. ; Gregg, Richard E. ; Lackner, Karl J. ; Fojo, Silvia S. ; Anchors, Michael A. ; Bojanovski, Marina ; Sprecher, Dennis L. ; Brewer, H.Bryan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-796ccceea4656bf16f3008b92283e863e1675ee1de0f7982c584a75f707a04d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Apolipoproteins B - blood</topic><topic>Biological and medical sciences</topic><topic>Cholesterol - blood</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Cholesterol, VLDL</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hyperlipoproteinemia Type II - diet therapy</topic><topic>Hyperlipoproteinemia Type II - drug therapy</topic><topic>Lipids - blood</topic><topic>Lipoproteins - blood</topic><topic>Lipoproteins, VLDL - blood</topic><topic>Lovastatin</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Naphthalenes - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>Random Allocation</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoeg, Jeffrey M.</creatorcontrib><creatorcontrib>Maher, Martha B.</creatorcontrib><creatorcontrib>Zech, Loren A.</creatorcontrib><creatorcontrib>Bailey, Kent R.</creatorcontrib><creatorcontrib>Gregg, Richard E.</creatorcontrib><creatorcontrib>Lackner, Karl J.</creatorcontrib><creatorcontrib>Fojo, Silvia S.</creatorcontrib><creatorcontrib>Anchors, Michael A.</creatorcontrib><creatorcontrib>Bojanovski, Marina</creatorcontrib><creatorcontrib>Sprecher, Dennis L.</creatorcontrib><creatorcontrib>Brewer, H.Bryan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoeg, Jeffrey M.</au><au>Maher, Martha B.</au><au>Zech, Loren A.</au><au>Bailey, Kent R.</au><au>Gregg, Richard E.</au><au>Lackner, Karl J.</au><au>Fojo, Silvia S.</au><au>Anchors, Michael A.</au><au>Bojanovski, Marina</au><au>Sprecher, Dennis L.</au><au>Brewer, H.Bryan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>1986-04-15</date><risdate>1986</risdate><volume>57</volume><issue>11</issue><spage>933</spage><epage>939</epage><pages>933-939</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p < 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p < 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>3515897</pmid><doi>10.1016/0002-9149(86)90733-2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 1986-04, Vol.57 (11), p.933-939 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76775494 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Anticholesteremic Agents - therapeutic use Apolipoproteins B - blood Biological and medical sciences Cholesterol - blood Cholesterol, HDL - blood Cholesterol, LDL - blood Cholesterol, VLDL Clinical Trials as Topic Double-Blind Method Female General and cellular metabolism. Vitamins Humans Hyperlipoproteinemia Type II - diet therapy Hyperlipoproteinemia Type II - drug therapy Lipids - blood Lipoproteins - blood Lipoproteins, VLDL - blood Lovastatin Male Medical sciences Middle Aged Naphthalenes - therapeutic use Pharmacology. Drug treatments Placebos Random Allocation Triglycerides - blood |
| title | Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A36%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20mevinolin%20on%20plasma%20lipoprotein%20concentrations%20in%20type%20II%20hyperlipoproteinemia&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Hoeg,%20Jeffrey%20M.&rft.date=1986-04-15&rft.volume=57&rft.issue=11&rft.spage=933&rft.epage=939&rft.pages=933-939&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/0002-9149(86)90733-2&rft_dat=%3Cproquest_cross%3E76775494%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76775494&rft_id=info:pmid/3515897&rft_els_id=0002914986907332&rfr_iscdi=true |